Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 30:11:740.
doi: 10.3389/fneur.2020.00740. eCollection 2020.

Chitosan-Based Non-viral Gene and Drug Delivery Systems for Brain Cancer

Affiliations
Review

Chitosan-Based Non-viral Gene and Drug Delivery Systems for Brain Cancer

Montserrat Lara-Velazquez et al. Front Neurol. .

Abstract

Central nervous system (CNS) tumors are a leading source of morbidity and mortality worldwide. Today, different strategies have been developed to allow targeted and controlled drug delivery into the brain. Gene therapy is a system based on the modification of patient's cells through the introduction of genetic material to exert a specific action. Administration of the foreign genetic material can be done through viral-mediated delivery or non-viral delivery via physical or mechanical systems. For brain cancer specifically, gene therapy can overcome the actual challenge of blood brain barrier penetration, the main reason for therapeutic failure. Chitosan (CS), a natural based biodegradable polymer obtained from the exoskeleton of crustaceans such as crab, shrimp, and lobster, has been used as a delivery vehicle in several non-viral modification strategies. This cationic polysaccharide is highly suitable for gene delivery mainly due to its chemical properties, its non-toxic nature, its capacity to protect nucleic acids through the formation of complexes with the genetic material, and its ease of degradation in organic environments. Recent evidence supports the use of CS as an alternative gene delivery system for cancer treatment. This review will describe multiple studies highlighting the advantages and challenges of CS-based delivery structures for the treatment of brain tumors. Furthermore, this review will provide insight on the translational potential of various CS based-strategies in current clinical cancer studies. Specifically, CS-based nanostructures including nanocapsules, nanospheres, solid-gel formulations, and nanoemulsions, also microshperes and micelles will be evaluated.

Keywords: biodegradable; biomaterials; brain cancer; brain tumor; chitosan; drug delivery; nanodelivery; nanoparticles.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chitosan based formulations for brain cancer. (A) Representation of the chemical conversion from chitin to chitosan. (B) Nanoparticles, nanocapsules, and micelles are some examples of chitosan formulations described in this review (Images from A,B were obtained from wikimedia commons without any modifications. Chitosan synthesis image by neurotiker, nanoparticles image design by HiguchiJu, nanocapsules image by Stephan Weiss and micelles image by Mariana Ruiz Villareal).

References

    1. Kochanek KD, Murphy SL, Xu J, Arias E. Deaths: Final Data for 2016. National Vital Statistics Reports. National Center for Health Statistics; (2018). - PubMed
    1. Dagenais GR, Leong DP, Rangarajan S, Lanas F, Lopez-Jaramillo P, Gupta R, et al. . Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet. (2019) 395:785–94. 10.1016/S0140-6736(19)32007-0 - DOI - PubMed
    1. Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo Clin Proc. (2007) 82:1271–86. 10.4065/82.10.1271 - DOI - PubMed
    1. Fuller CE, Jones DTW, Kieran MW. New classification for central nervous system tumors: implications for diagnosis and therapy. Am Soc Clin Oncol Educ Book. (2017) 37:753–63. 10.14694/EDBK_175088 - DOI - PubMed
    1. Kirkpatrick JP, Sampson JH. Recurrent malignant gliomas. Semin Radiat Oncol. (2014) 24:289–98. 10.1016/j.semradonc.2014.06.006 - DOI - PMC - PubMed

LinkOut - more resources